SS
THRX

Steve Schonfeld’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Steve Schonfeld’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-78,369
Closed -$696K – 2628
2023
Q1 		$696K Buy
+78,369
New +$769K 0.01% 1071

Other funds holding THRX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Steve Schonfeld's THRX Position: Q2 2023 in Review

Steve Schonfeld sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q2 2023, closing a stake of 78,369 shares — an estimated $696K sold.

Steve Schonfeld first reported a position in THRX in Q1 2023 and held it in 1 quarter. The position peaked at $696K in Q1 2023. 69 funds tracked by Wall St. Rank hold THRX as of Q2 2023.

  • Steve Schonfeld reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Steve Schonfeld sold 78,369 Theseus Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $696K.
  • Steve Schonfeld first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Steve Schonfeld's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $696K in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.